Impact of different cut-off limits of peak GH after @entity7704 -arginine stimulatory test, single @entity442 measurement, or their combination in identifying adult XXXX with GH deficiency.

@entity1 @entity7704 @entity442 @entity534 @entity29983 @entity51
OBJECTIVE: To evaluate the impact of different peak GH cut-off limits after @entity7704 - @entity534 test, @entity442 measurement, or their combination in identifying @entity1 with @entity51 ( @entity51 ). DESIGN AND @entity1 : Totally, 894 normal subjects (used for determining @entity442 normative limits) and 302 @entity1 with suspected @entity51 were included. Different peak GH cut-off limits (used by European (depending on body mass index (BMI)) or North American (4.1 g/l) Endocrine Societies, by HypoCCs (2.5 g/l), or with 95% specificity (based on BMI), Method 1, 2, 3, or 4 respectively) and @entity442 were considered. METHODS: Peak GH after @entity7704 - @entity534 and @entity442 . RESULTS: Different peak GH cut-off limits recognized different proportions of @entity51 (range, 24.8-62.9%). Methods 1 and 2 with high sensitivity recognized a higher proportion (95.5 and 92.5% respectively) of @entity51 among @entity1 with three (T) @entity51 ( @entity51 ), whereas Method 4 (with high specificity) identified 96.7% normal subjects among those without pituitary @entity51 ; on the contrary, Method 4 identified only 75% @entity51 among @entity1 with @entity29983 , whereas Method 1 recognized a high proportion (40%) of @entity51 among subjects without @entity51 . Of the total @entity1 , 82% with @entity29983 and 84.5% without @entity51 were recognized as @entity51 or normal respectively by @entity442 . Among the remaining @entity1 with @entity29983 and normal @entity442 , 75% was recognized as @entity51 by Method 1; among @entity1 without @entity51 and abnormal @entity442 , 87.5% was identified as normal by Method 4. Overall, combination of @entity442 and Method 1 or Method 4 identified 95.5% @entity51 among @entity1 with @entity29983 and 98.1% normal subjects among those without @entity51 . CONCLUSIONS: Single peak GH cut-offs have limits to sharply differentiate @entity51 from normal subjects; @entity442 may be used for selecting @entity1 to be submitted to the @entity7704 - @entity534 test; the peak GH cut-off limits to be used for identifying healthy or diseased @entity1 depend mainly on the clinical context.
